- Home
- PDX vs ZYME Comparison
PDX vs ZYME Comparison
Compare PDX & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDX
- ZYME
- Stock Information
- Founded
- PDX 2019
- ZYME 2003
- Country
- PDX NY
- ZYME United States
- Employees
- PDX N/A
- ZYME N/A
- Industry
- PDX Finance/Investors Services
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- PDX Finance
- ZYME Health Care
- Exchange
- PDX Nasdaq
- ZYME Nasdaq
- Market Cap
- PDX 1.2B
- ZYME 956.0M
- IPO Year
- PDX N/A
- ZYME 2017
- Fundamental
- Price
- PDX $31.82
- ZYME $14.29
- Analyst Decision
- PDX
- ZYME Buy
- Analyst Count
- PDX 0
- ZYME 6
- Target Price
- PDX N/A
- ZYME $19.17
- AVG Volume (30 Days)
- PDX N/A
- ZYME 544.8K
- Earning Date
- PDX 01-01-0001
- ZYME 03-05-2025
- Dividend Yield
- PDX 4.95%
- ZYME N/A
- EPS Growth
- PDX N/A
- ZYME N/A
- EPS
- PDX N/A
- ZYME N/A
- Revenue
- PDX N/A
- ZYME $62,199,000.00
- Revenue This Year
- PDX N/A
- ZYME $21.53
- Revenue Next Year
- PDX N/A
- ZYME N/A
- P/E Ratio
- PDX N/A
- ZYME N/A
- Revenue Growth
- PDX N/A
- ZYME N/A
- 52 Week Low
- PDX $13.52
- ZYME $7.97
- 52 Week High
- PDX $21.05
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- PDX 73.23
- ZYME 52.48
- Support Level
- PDX $30.73
- ZYME $13.58
- Resistance Level
- PDX $32.65
- ZYME $14.63
- Average True Range (ATR)
- PDX 1.05
- ZYME 0.84
- MACD
- PDX 0.60
- ZYME -0.01
- Stochastic Oscillator
- PDX 85.17
- ZYME 34.89
About PDX PIMCO Dynamic Income Strategy Fund of Beneficial Interest
PIMCO Dynamic Income Strategy Fund is a non-diversified, limited term, closed-end management investment company registered under the Investment Company. The fund's primary investment objective is to seek current income as a primary objective and capital appreciation as a secondary objective.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.